Arcus Biosciences RCUS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $201M+4.7% | $222M+48.0% | $238M+18.4% | $248M+59.0% | $192M+3.8% | ||
| $621M-22.9% | $759M-8.3% | $593M-33.2% | $663M-18.5% | $805M-0.6% | ||
| $844M-18.1% | $1.01B-0.9% | $857M-24.0% | $946M-7.4% | $1.03B-3.1% | ||
| $38M-17.4% | $40M-14.9% | $42M-12.5% | $44M-10.2% | $46M-9.8% | ||
| $997M-13.8% | $1.14B-1.0% | $974M-22.2% | $1.08B-9.4% | $1.16B-10.6% | ||
| $39M+77.3% | $42M+133% | $42M+223% | $29M+93.3% | $22M+37.5% | ||
| $34M-52.8% | $35M-58.8% | $52M-50.5% | $71M-37.2% | $72M-41.9% | ||
| $209M+8.9% | $231M+2.2% | $235M+9.3% | $210M+5.5% | $192M-5.9% | ||
| $100M— | $99M— | $98M— | $97M— | —— | ||
| 400M0.0% | 400M-75.3% | 400M0.0% | 400M0.0% | 400M0.0% | ||
| -$1.61B-29.7% | -$1.49B-31.2% | -$1.38B-32.9% | -$1.24B-31.5% | -$1.24B-45.8% | ||
| $524M-1.3% | $631M+30.1% | $436M-22.8% | $549M-13.5% | $531M-24.9% | ||
| $997M-13.8% | $1.14B-1.0% | $974M-22.2% | $1.08B-9.4% | $1.16B-10.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Arcus Biosciences cover its short-term obligations?
- Its current ratio is 4.04 — current assets exceed current liabilities.
- Where does Arcus Biosciences's balance sheet data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.